Pancreatic Cancer Research

ResearcherNational Institutes for Quantum Science and TechnologyNo recent work listed

Tatsuya Higashi

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-8338-4737; OpenAlex author ID A5067101373, A5103583573. Sources: OpenAlex.

Their work

Papers
12 (first author 0, last author 8)
Trials
0
Grants
0
Labs led
1
Collaborators
14
Papers, trials and grants by year

2017: 1 paper · 2018: 2 papers · 2019: 2 papers · 2020: 1 paper · 2021: 3 papers · 2022: 3 papers

Papers 12

  1. The natural sulfoglycolipid derivative SQAP improves the therapeutic efficacy of tissue factor-targeted radioimmunotherapy in the stroma-rich pancreatic cancer… Last author DOI 10.1016/j.tranon.2021.101285↗
  2. In Vitro Tumor Cell-Binding Assay to Select High-Binding Antibody and Predict Therapy Response for Personalized 64Cu-Intraperitoneal Radioimmunotherapy against… Co-author DOI 10.3390/ijms23105807↗
  3. Preclinical Safety Evaluation of Intraperitoneally Administered Cu-Conjugated Anti-EGFR Antibody NCAB001 for the Early Diagnosis of Pancreatic Cancer Using PET. Co-author DOI 10.3390/pharmaceutics14091928↗
  4. Usefulness of PET-guided surgery with 64Cu-labeled cetuximab for resection of intrapancreatic residual tumors in a xenograft mouse model of resectable pancreat… Last author DOI 10.1097/mnm.0000000000001442↗
  5. Evaluation of 64Cu-Labeled New Anti-EGFR Antibody NCAB001 with Intraperitoneal Injection for Early PET Diagnosis of Pancreatic Cancer in Orthotopic Tumor-Xenog… Co-author DOI 10.3390/ph14100950↗
  6. Characterization and Stabilization of a New 64Cu-Labeled Anti-EGFR Antibody NCAB001 for the Early Detection of Pancreatic Cancer with Positron Emission Tomogra… Co-author DOI 10.3390/pharmaceutics14010067↗
  7. Immuno-OpenPET: a novel approach for early diagnosis and image-guided surgery for small resectable pancreatic cancer. Last author DOI 10.1038/s41598-020-61056-5↗
  8. 64Cu-Intraperitoneal Radioimmunotherapy: A Novel Approach for Adjuvant Treatment in a Clinically Relevant Preclinical Model of Pancreatic Cancer. Last author DOI 10.2967/jnumed.118.225045↗
  9. Anti‑tissue factor antibody‑mediated immuno‑SPECT imaging of tissue factor expression in mouse models of pancreatic cancer. Last author DOI 10.3892/or.2019.7017↗
  10. Efficacy Evaluation of Combination Treatment Using Gemcitabine and Radioimmunotherapy with 90Y-Labeled Fully Human Anti-CD147 Monoclonal Antibody 059-053 in a … Last author DOI 10.3390/ijms19102979↗
  11. Near-infrared photoimmunotherapy of pancreatic cancer using an indocyanine green-labeled anti-tissue factor antibody. Last author DOI 10.3748/wjg.v24.i48.5491↗
  12. Combined treatment of pancreatic cancer xenograft with 90Y-ITGA6B4-mediated radioimmunotherapy and PI3K/mTOR inhibitor. Last author DOI 10.3748/wjg.v23.i42.7551↗

Closest collaborators

The 14 strongest of 14 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Aya Sugyo · 9 shared papers, 2017–2022 · strength 0.91
  2. Yukie Yoshii · 7 shared papers, 2019–2022 · strength 0.78
  3. Hiroki Matsumoto · 7 shared papers, 2019–2022 · strength 0.78
  4. Fukiko Hihara · 6 shared papers, 2020–2022 · strength 0.68
  5. Chika Igarashi · 6 shared papers, 2020–2022 · strength 0.68
  6. Makoto Ueno · 4 shared papers, 2021–2022 · strength 0.48
  7. Mitsuyoshi Yoshimoto · 4 shared papers, 2019–2022 · strength 0.42
  8. Masahiro Yasunaga · 3 shared papers, 2018–2022 · strength 0.34
  9. Yasuhiro Matsumura · 3 shared papers, 2018–2022 · strength 0.34
  10. Winn Aung U · 3 shared papers, 2017–2019 · strength 0.25
  11. Tsuneo Saga · 3 shared papers, 2017–2019 · strength 0.25
  12. Yoichi Takakusagi · 1 shared paper, 2022 · strength 0.16
  13. Tadashi Watabe · 1 shared paper, 2021 · strength 0.10
  14. Jun Hatazawa · 1 shared paper, 2021 · strength 0.10

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.